RDHL

Redhill Biopharm

• TipRanks·04/30 12:16

  RedHill Biopharma Reports Promising MAP-Killing Data for Next-Generation Crohn’s Candidate RHB-204

• TipRanks·04/30 11:52

  RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease

• Benzinga·04/30 11:12

  Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy

• PR Newswire·04/30 11:00

  RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

• TipRanks·04/27 12:29

  RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results

• Benzinga·04/27 12:14

  Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY

• Seeking Alpha·04/27 12:02

  RedHill GAAP EPS of $0.00, revenue of $0.29M

• PR Newswire·04/27 12:00

  RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

• TipRanks·04/22 12:40

  RedHill Biopharma announces presentation of preclinical data on opaganib at AACR

• TipRanks·04/22 12:28

  RedHill Biopharma Showcases New Opaganib Preclinical Data in Neuroblastoma and Triple-Negative Breast Cancer at AACR 2026

• Benzinga·04/22 12:06

  RedHill Presents New Preclinical Showing Effects Of Opaganib As Potential Add-On Therapy In Models Of Retinoblastoma And Triple-Negative Breast Cancer At AACR Annual Meeting.

• TipRanks·04/14 11:28

  RedHill Biopharma Receives Nasdaq Minimum Bid Price Deficiency Notice

• TipRanks·03/05 14:32

  RedHill Biopharma Shareholders Approve RSU Grants and Share Capital Increase

• Reuters·03/03 22:12

  Cumberland Pharmaceuticals 2025 revenue rises 

• TipRanks·02/25 12:17

  RedHill Biopharma announces full sales and operational launch of Talicia